Your browser is no longer supported. Please, upgrade your browser.
Akebia Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.91 Insider Own0.30% Shs Outstand173.78M Perf Week-6.55%
Market Cap445.30M Forward P/E- EPS next Y-0.69 Insider Trans-1.07% Shs Float172.71M Perf Month-17.89%
Income-299.20M PEG- EPS next Q-0.09 Inst Own59.60% Short Float5.98% Perf Quarter-15.74%
Sales210.70M P/S2.11 EPS this Y-17.20% Inst Trans-6.87% Short Ratio5.04 Perf Half Y-22.82%
Book/sh0.79 P/B3.25 EPS next Y50.90% ROA-48.10% Target Price6.54 Perf Year-17.36%
Cash/sh1.20 P/C2.15 EPS next 5Y- ROE-154.70% 52W Range2.35 - 5.14 Perf YTD-8.21%
Dividend- P/FCF- EPS past 5Y-3.80% ROI-109.40% 52W High-50.00% Beta1.56
Dividend %- Quick Ratio1.60 Sales past 5Y- Gross Margin35.70% 52W Low9.36% ATR0.15
Employees380 Current Ratio1.70 Sales Q/Q-18.70% Oper. Margin- RSI (14)39.16 Volatility5.56% 5.48%
OptionableYes Debt/Eq0.71 EPS Q/Q18.10% Profit Margin- Rel Volume1.60 Prev Close2.71
ShortableYes LT Debt/Eq0.71 EarningsNov 04 BMO Payout- Avg Volume2.05M Price2.57
Recom2.20 SMA20-10.01% SMA50-10.28% SMA200-17.84% Volume3,287,899 Change-5.17%
Mar-08-21Initiated Cantor Fitzgerald Overweight $8
Jan-29-21Downgrade JP Morgan Neutral → Underweight
Nov-14-19Reiterated Needham Buy $18 → $15
Aug-06-19Reiterated H.C. Wainwright Buy $19 → $17
Jul-11-19Reiterated H.C. Wainwright Buy $23 → $21
May-02-19Initiated JP Morgan Overweight $12
Mar-20-19Initiated Citigroup Neutral $9
Sep-07-18Resumed Morgan Stanley Equal-Weight
Aug-10-18Reiterated Needham Buy $20 → $18
Jun-06-18Reiterated H.C. Wainwright Buy $24 → $22
Dec-19-17Initiated Piper Jaffray Overweight $26
Dec-07-17Initiated BTIG Research Buy $30
Sep-15-17Initiated RBC Capital Mkts Sector Perform $17
Jul-10-17Reiterated H.C. Wainwright Buy $25 → $24
Apr-27-17Reiterated Needham Buy $14 → $18
Apr-27-17Reiterated H.C. Wainwright Buy $18 → $21
Dec-27-16Reiterated H.C. Wainwright Buy $17 → $18
Dec-20-16Reiterated JMP Securities Mkt Outperform $16 → $19
Nov-15-16Initiated Aegis Capital Buy
Sep-29-16Initiated Brean Capital Buy
Dec-01-21 04:25PM  
Nov-24-21 08:30AM  
Nov-15-21 08:30AM  
Nov-14-21 08:53AM  
Nov-09-21 11:31PM  
Nov-04-21 09:25AM  
Nov-01-21 04:05PM  
Oct-29-21 08:00AM  
Oct-28-21 03:06PM  
Oct-26-21 08:00AM  
Oct-25-21 04:39PM  
Oct-21-21 06:34AM  
Oct-18-21 08:00AM  
Oct-01-21 04:05PM  
Sep-06-21 06:23AM  
Sep-01-21 04:05PM  
Aug-05-21 04:31PM  
Aug-03-21 04:05PM  
Jul-29-21 03:05PM  
Jul-27-21 06:15PM  
Jul-26-21 01:47PM  
Jul-01-21 04:05PM  
Jun-18-21 12:58PM  
Jun-08-21 01:20AM  
Jun-04-21 10:27AM  
Jun-03-21 08:00AM  
Jun-02-21 04:05PM  
Jun-01-21 06:00AM  
May-25-21 08:10AM  
May-12-21 09:11AM  
May-10-21 09:20AM  
May-04-21 04:05PM  
Apr-28-21 05:19PM  
Apr-26-21 08:15AM  
Apr-24-21 03:16AM  
Apr-12-21 08:00AM  
Apr-02-21 04:05PM  
Mar-31-21 09:24AM  
Mar-30-21 06:00AM  
Mar-25-21 08:00AM  
Mar-24-21 08:00AM  
Mar-11-21 08:00AM  
Mar-09-21 11:32PM  
Mar-02-21 04:05PM  
Feb-25-21 12:47PM  
Feb-18-21 08:00AM  
Feb-08-21 08:00AM  
Feb-02-21 04:05PM  
Feb-01-21 10:05PM  
Jan-29-21 10:32AM  
Jan-06-21 08:00AM  
Jan-05-21 04:05PM  
Jan-04-21 08:00AM  
Dec-16-20 02:16PM  
Dec-09-20 08:00AM  
Dec-02-20 04:05PM  
Nov-24-20 08:00AM  
Nov-18-20 09:37AM  
Nov-16-20 08:30AM  
Nov-12-20 08:40AM  
Nov-10-20 05:01AM  
Nov-07-20 07:18AM  
Nov-05-20 11:31PM  
Nov-03-20 04:05PM  
Oct-29-20 12:35PM  
Oct-26-20 08:00AM  
Oct-23-20 11:15AM  
Oct-22-20 05:05PM  
Oct-13-20 08:40AM  
Oct-09-20 04:49PM  
Oct-08-20 08:54AM  
Oct-02-20 04:05PM  
Sep-29-20 05:27PM  
Sep-26-20 08:50AM  
Sep-08-20 08:00AM  
Sep-04-20 12:55PM  
Sep-03-20 11:55AM  
Sep-02-20 04:05PM  
Aug-26-20 08:41AM  
Aug-12-20 07:08AM  
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Burke Steven KeithSVP, Chief Medical OfficerAug 31Sale2.831,0422,949171,219Sep 02 04:07 PM
GILMAN STEVEN CDirectorJun 07Sale3.324,56715,16347,997Jun 09 04:26 PM
Butler John P.CEO and PresidentMar 01Sale3.4049,990169,7711,116,742Mar 02 04:10 PM
Dahan MichelSVP, Chief Operating OfficerMar 01Sale3.4014,54749,403255,113Mar 02 04:08 PM
Hadas Nicole R.SVP, Chief Legal OfficerMar 01Sale3.4014,28548,513263,171Mar 02 04:08 PM
Faulkingham DellCCOMar 01Sale3.406,74922,920128,825Mar 02 04:08 PM
Burke Steven KeithSVP, Chief Medical OfficerMar 01Sale3.407,55825,668161,442Mar 02 04:06 PM